JPRN-UMIN000009901已完成3 期
A Multicenter, Open-label, Prospective Randomized Controlled Trial to evaluate the Effect of Low-Molecular-Weight Heparin on Prevention of Venous Thromboembolism after Laparoscopic Surgery - Effect of LMWH on Prevention of VTE after Laparoscopic Surgery
Division of Gastrointestinal Surgery, Department of Surgery, Tohoku University Hospital0 个研究点目标入组 400 人开始时间: 2013年2月1日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 40years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)History of allergic reaction to heparin and / or heparinoid, or heparin-induced thrombocytopenia 2)Coexistence / past history of acute bacterial endocarditis 3)Moderate to severe renal dysfunction (50mL/min >= CCr) 4)Severe liver dysfunction 5)Body weight under 40 Kg 6)During pregnancy and lactation 7)Administration of anticoagulant and / or antiplatelet agent such as warfarin, aspirin and clopidogrel sulfate before operation. 8)Morbid obesity (30<=BMI) 9)Coexistence / clinical sign of venous thromboembolism, past history of venous thromboembolism within one year till the scheduled date of surgery 10)With indwelling central venous catheter 11)Administration of estrogen / progesteronal agents within four weeks prior to the operation. 12)Neo-adjuvant chemotherapy /radiotherapy within four weeks prior to the operation 13)Abnormal high value of D-dimer (=> 10 microg/mL) within four weeks prior to the operation 14)Any other condition that, in the investigator's opinion, places the subject at undue risk by participating in the study
研究者
相似试验
尚未招募
Unknown
A Multicenter, Prospective, Open-label, Randomized Controlled Study to Evaluate the Safety of Short-term Dual Antiplatelet Therapy after Coronary Stenting with the Everolimus-Eluting Stent in Patients with Coronary artery diseaseDiseases of the circulatory systemKCT0008411Seoul National University Bundang Hospital2,018
招募中
3 期
A Prospective, Open-label, Multicenter, Randomized Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Renal Allograft Recipients Aged 12 to Less Than 18 Years of Age to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive MedicationsKidney transplantRenal Allograft10038430NL-OMON52226Bristol-Myers Squibb3
进行中（未招募）
1 期
Evaluation of Conversion from Calcineurin Inhibitor- to Belatacept-based Immunosuppression in Adolescent Renal Transplant Recipients and their Compliance with Immunosuppressive MedicationsAdolescent Renal AllograftsMedDRA version: 21.0Level: PTClassification code 10038533Term: Renal transplantSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2018-000237-12-FRBristol-Myers Squibb International Corporation120
招募中
1 期
Evaluation of Conversion from Calcineurin Inhibitor- to Belatacept-based Immunosuppression inAdolescent Renal Transplant Recipients and their Compliance with ImmunosuppressiveMedicationsAdolescent Renal AllograftsMedDRA version: 21.0Level: PTClassification code: 10038533Term: Renal transplant Class: 100000004865CTIS2022-501677-39-00Bristol Myers Squibb International Corporation109
进行中（未招募）
1 期
Evaluation of Conversion from Calcineurin Inhibitor- to Belatacept-based Immunosuppression in Adolescent Renal Transplant Recipients and their Compliance with Immunosuppressive MedicationsAdolescent Renal AllograftsMedDRA version: 21.0Level: PTClassification code 10038533Term: Renal transplantSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2018-000237-12-NLBristol-Myers Squibb International Corporation120